PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
China Resources Pharmaceutical Group Ltd (3320.HK)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN

HK0000311099

Sector

Healthcare

Highlights

Market Cap

HK$33.99B

PE Ratio

8.59

PEG Ratio

5.20

Year Range

HK$4.24 - HK$7.11

Target Price

HK$7.13

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Performance

Performance Chart

The chart shows the growth of an initial investment of HK$10,000 in China Resources Pharmaceutical Group Ltd, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


-10.00%0.00%10.00%20.00%JulyAugustSeptemberOctoberNovemberDecember
-5.32%
11.72%
3320.HK (China Resources Pharmaceutical Group Ltd)
Benchmark (^GSPC)

Returns By Period

China Resources Pharmaceutical Group Ltd had a return of 9.14% year-to-date (YTD) and 17.13% in the last 12 months.


3320.HK

YTD

9.14%

1M

-6.15%

6M

-5.32%

1Y

17.13%

5Y (annualized)

-2.30%

10Y (annualized)

N/A

^GSPC (Benchmark)

YTD

26.52%

1M

0.66%

6M

12.27%

1Y

30.56%

5Y (annualized)

13.80%

10Y (annualized)

11.69%

Monthly Returns

The table below presents the monthly returns of 3320.HK, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2024-7.21%11.34%-5.66%1.60%13.97%3.03%-7.77%3.00%11.21%-8.49%-4.55%9.14%
2023-6.65%9.32%-3.57%25.08%-3.47%-7.23%-11.29%-13.39%-0.76%-6.54%0.41%5.12%-17.08%
20227.04%1.58%5.70%2.20%4.08%27.43%-11.82%14.47%0.19%-1.67%20.75%-1.25%84.72%
20212.51%21.32%-2.02%8.25%6.09%-11.16%-14.05%-2.64%-5.43%-2.09%-9.60%4.72%-8.81%
2020-9.68%3.83%-31.42%5.38%-13.88%11.43%-1.57%-0.23%-9.34%-2.76%8.27%-5.01%-42.09%
20199.00%-5.57%5.51%0.54%-8.24%-12.86%-2.72%-5.48%-9.26%-1.36%-5.66%5.70%-28.35%
20181.78%2.52%4.17%-1.27%11.97%-9.80%5.16%9.98%-1.11%-7.41%0.00%-11.13%2.00%
2017-3.54%-0.35%7.97%0.88%0.24%7.26%-3.90%3.52%-4.33%2.37%9.05%-2.32%16.83%
20160.11%-4.66%1.74%-2.89%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of 3320.HK is 53, suggesting that the investment has average results relative to other stocks in terms of risk-adjusted performance. This ranking is determined by the cumulative values of the indicators listed below.


The Risk-Adjusted Performance Rank of 3320.HK is 5353
Overall Rank
The Sharpe Ratio Rank of 3320.HK is 5656
Sharpe Ratio Rank
The Sortino Ratio Rank of 3320.HK is 5050
Sortino Ratio Rank
The Omega Ratio Rank of 3320.HK is 4848
Omega Ratio Rank
The Calmar Ratio Rank of 3320.HK is 5353
Calmar Ratio Rank
The Martin Ratio Rank of 3320.HK is 5656
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for China Resources Pharmaceutical Group Ltd (3320.HK) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


Sharpe ratio
The chart of Sharpe ratio for 3320.HK, currently valued at 0.38, compared to the broader market-4.00-2.000.002.000.382.54
The chart of Sortino ratio for 3320.HK, currently valued at 0.83, compared to the broader market-4.00-2.000.002.004.000.833.39
The chart of Omega ratio for 3320.HK, currently valued at 1.10, compared to the broader market0.501.001.502.001.101.47
The chart of Calmar ratio for 3320.HK, currently valued at 0.25, compared to the broader market0.002.004.006.000.253.66
The chart of Martin ratio for 3320.HK, currently valued at 1.24, compared to the broader market-10.000.0010.0020.0030.001.2416.25
3320.HK
^GSPC

The current China Resources Pharmaceutical Group Ltd Sharpe ratio is 0.38. This value is calculated based on the past 1 year of trading data and takes into account price changes and dividends.

Use the chart below to compare the Sharpe ratio of China Resources Pharmaceutical Group Ltd with the selected benchmark, providing insights into the investment's historical performance in terms of risk-adjusted returns. Go to the Sharpe ratio tool for more fine-grained control over the calculation options.


Rolling 12-month Sharpe Ratio-1.000.001.002.003.00JulyAugustSeptemberOctoberNovemberDecember
0.38
2.48
3320.HK (China Resources Pharmaceutical Group Ltd)
Benchmark (^GSPC)

Dividends

Dividend History

China Resources Pharmaceutical Group Ltd provided a 4.88% dividend yield over the last twelve months, with an annual payout of HK$0.26 per share. The company has been increasing its dividends for 2 consecutive years.


1.00%2.00%3.00%4.00%5.00%6.00%HK$0.00HK$0.05HK$0.10HK$0.15HK$0.202017201820192020202120222023
Dividends
Dividend Yield
PeriodTTM2023202220212020201920182017
DividendHK$0.26HK$0.16HK$0.15HK$0.12HK$0.22HK$0.13HK$0.11HK$0.09

Dividend yield

4.88%3.12%2.37%3.38%5.53%1.80%1.08%0.89%

Monthly Dividends

The table displays the monthly dividend distributions for China Resources Pharmaceutical Group Ltd. The dividends shown in the table have been adjusted to account for any splits that may have occurred.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2024HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.17HK$0.00HK$0.00HK$0.09HK$0.00HK$0.00HK$0.00HK$0.26
2023HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.16HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.16
2022HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.15HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.15
2021HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.12HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.12
2020HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.22HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.22
2019HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.13HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.13
2018HK$0.00HK$0.00HK$0.00HK$0.00HK$0.11HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.11
2017HK$0.09HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.09

Dividend Yield & Payout


Dividend Yield
5.0%10.0%15.0%4.9%
China Resources Pharmaceutical Group Ltd has a dividend yield of 4.88%, which is quite average when compared to the overall market.
Payout Ratio
200.0%400.0%600.0%800.0%26.1%
China Resources Pharmaceutical Group Ltd has a payout ratio of 26.14%, which is quite average when compared to the overall market. This suggests that China Resources Pharmaceutical Group Ltd strikes a balance between reinvesting profits for growth and paying dividends to shareholders.

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


-50.00%-40.00%-30.00%-20.00%-10.00%0.00%JulyAugustSeptemberOctoberNovemberDecember
-49.41%
-0.98%
3320.HK (China Resources Pharmaceutical Group Ltd)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the China Resources Pharmaceutical Group Ltd. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the China Resources Pharmaceutical Group Ltd was 72.81%, occurring on Dec 20, 2021. The portfolio has not yet recovered.

The current China Resources Pharmaceutical Group Ltd drawdown is 49.41%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-72.81%Sep 4, 2018813Dec 20, 2021
-19.23%Apr 9, 201860Jul 5, 201839Aug 29, 201899
-10.08%Jul 4, 201729Aug 11, 201766Nov 16, 201795
-8.84%Jan 22, 201815Feb 9, 20185Feb 20, 201820
-8.72%Nov 17, 201714Dec 6, 201719Jan 5, 201833

Volatility

Volatility Chart

The current China Resources Pharmaceutical Group Ltd volatility is 6.75%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%5.00%10.00%15.00%20.00%JulyAugustSeptemberOctoberNovemberDecember
6.75%
2.23%
3320.HK (China Resources Pharmaceutical Group Ltd)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of China Resources Pharmaceutical Group Ltd over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Valuation

The Valuation section provides an assessment of the market value of China Resources Pharmaceutical Group Ltd compared to its peers in the Drug Manufacturers - Specialty & Generic industry.


PE Ratio
20.040.060.080.0100.08.6
The chart displays the price to earnings (P/E) ratio for 3320.HK in comparison to other companies of the Drug Manufacturers - Specialty & Generic industry. Currently, 3320.HK has a PE value of 8.6. This PE value is considered to be low compared to the rest of the industry.
PEG Ratio
-150.0-100.0-50.00.050.05.2
The chart displays the price to earnings to growth (PEG) ratio for 3320.HK in comparison to other companies of the Drug Manufacturers - Specialty & Generic industry. Currently, 3320.HK has a PEG value of 5.2. This PEG ratio is much higher than those of other companies of the industry. This might be an indicator of the company being overvalued.

Historical P/E Ratio Chart

The chart below displays the historical trend of the price-to-earnings (P/E) ratio for China Resources Pharmaceutical Group Ltd.


Loading data...

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2024 PortfoliosLab